Pulmonary-Allergy Drugs: An Interview With FDA's Badrul Chowdhury
This article was originally published in RPM Report
Executive Summary
The Division of Pulmonary-Allergy Drugs has seen a number of high profile drugs come through its review group. The RPM Report sat down with Division Director Badrul Chowdhury to talk about his philosophy of drug review, the REMS, biosimilars, and the role of drug safety in making approval decisions.